Published in final edited form as:

Bioorg Med Chem Lett. 2011 May 1; 21(9): 2756–2758. doi:10.1016/j.bmcl.2010.11.028.

Potential of ribonuclease cytotoxicity by a poly(amidoamine) dendrimer

Gregory A. Ellis^a, Megan L. Hornung^b, and Ronald T. Raines^{a,c}

^a Department of Biochemistry, University of Wisconsin–Madison, 433 Babcock Drive, Madison, WI 53706, USA

^b Department of Zoology, University of Wisconsin–Madison, 250 North Mills Street, Madison, WI 53706, USA

^c Department of Chemistry, University of Wisconsin–Madison, 1101 University Avenue, Madison, WI 53706, USA

Abstract

Variants of bovine pancreatic ribonuclease (RNase A) engineered to evade the endogenous ribonuclease inhibitor protein (RI) are toxic to human cancer cells. Increasing the basicity of these variants facilitates their entry into the cytosol and thus increases their cytotoxicity. The installation of additional positive charge also has the deleterious consequence of decreasing ribonucleolytic activity or conformational stability. Here, we report that the same benefit can be availed by co-treating cells with a cationic dendrimer. We find that adding the generation 2 poly(amidoamine) dendrimer in *trans* increases the cytotoxicity of RI-evasive RNase A variants without decreasing their activity or stability. The increased cytotoxicity is not due to increased RI-evasion or cellular internalization, but likely results from improved translocation into the cytosol after endocytosis. These data indicate that co-treatment with highly cationic molecules could enhance the efficacy of ribonucleases as chemotherapeutic agents.

Keywords

Cancer; Dendrimer; PAMAM; Poly(amidoamine); Ribonuclease; Ribonuclease inhibitor; Synergy

Pancreatic-type ribonucleases can be toxic to cancerous cells.^{1–5} This cytotoxicity depends on the efficiency of their internalization into cells and subsequent translocation into the cytosol, their conformational stability, their ability to evade the endogenous ribonuclease inhibitor protein (RI),⁶ and their ability to catalyze the degradation of cellular RNA.⁷ Although Onconase®,⁸ a ribonuclease from the Northern Leopard frog that naturally evades RI, is in a Phase IIIb clinical trial as a treatment for malignant mesothelioma, its therapeutic potential is diminished by dose-limiting renal toxicity.⁹ Mammalian pancreatic ribonucleases accumulate to a much lesser extent in the kidneys, but are strongly inhibited by RI.^{9–11} Variants of both bovine (RNase A12) and human (RNase 1) pancreatic ribonuclease have been engineered to evade RI and are thereby endowed with cytotoxic

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Supplementary Material

Supplementary data (experimental procedures and RI–dendrimer binding data) associated with this article can be found, in the online version, at doi:10.1016/j.bmcl.2010.xx.xxx.

activity.^{10·11·13·14} An RNase 1 variant is in a Phase I clinical trial for patients having advanced, refractory, solid tumors.

Although ribonucleases show promise as cancer chemotherapeutic agents, their potency is limited by the bottleneck of cellular internalization and translocation into the cytosol. For example, RNase A has cytotoxicity at much lower (*e.g.*, picomolar) concentrations when injected directly into cells.^{15·16} RNase A and its homologues are cationic proteins (Fig. 1). Internalization has been shown to correlate with ribonuclease cationicity,¹⁷ and efforts have been made to add positive charge and thereby enhance cytotoxicity. “Arginine-grafting” and appending a nonaarginine tag do indeed increase the cytotoxicity of RI-evasive RNase A variants.^{18·19} These alterations, however, tend to diminish the conformational stability of the ribonuclease, abrogating some of the benefit from increased internalization. RNase A has also been modified by condensing the side chains of aspartate and glutamate residues with ethylenediamine or cationic polymers of poly(ethyleneimine).^{21·22} Although these covalent modifications increase cytotoxicity, they diminish catalytic activity. We sought a means to increase ribonuclease-mediated cytotoxicity without compromising other desirable attributes.

To avoid the deleterious consequences of adding cationic groups to a ribonuclease, we hypothesized that ribonuclease cytotoxicity could be enhanced by adding a highly cationic molecule as a co-treatment, that is, in *trans*. This strategy was inspired by the recent observation that co-treatment with a cationic peptide enhances the cellular uptake of proteins.²³ As our co-treatment, we chose to use the generation 2 poly(amidoamine) (PAMAM) dendrimer (Figure 2), which has a high density of cationic charge. PAMAM dendrimers are monodisperse branched polymers that are available from numerous commercial vendors.^{24·25} PAMAM dendrimers have been employed as drug and gene delivery vehicles, as they have the ability to transport encapsulated small molecules and enwrapped DNA into cells.^{25–28} We chose the relatively small generation 2 dendrimer due to its low inherent cytotoxicity compared to higher generation dendrimers and other highly cationic macromolecules, such as polyethylenimine.^{29–31} This dendrimer has 16 primary amino groups and 14 tertiary amino groups. Its net molecular charge is approximately $Z = +16$,³² and could reach $Z = +30$ in an acidic environment. The dendrimer is known to enter cells through endocytosis and then appears to disrupt endosomes through the “proton sponge” effect, translocating into the cytosol.³³ We reasoned that dendrimers could elicit an adventitious increase in the translocation of ribonucleases into the cytosol and, thus, in their cytotoxic activity.

Ribonucleases tend to lose conformational stability^{18·19} or catalytic activity^{21·22} when modified covalently to be more cationic. Accordingly, we first sought to discern whether the dendrimer elicited any effects on these important attributes in *trans*. We found that the dendrimer at concentrations of 1 or 10 μM has no discernable effect on the thermostability of RNase A (Table 1). Similarly, these concentrations had an insignificant effect on ribonucleolytic activity. Accordingly, we conclude that the dendrimer at a concentration of $\leq 10 \mu\text{M}$ has no deleterious consequences.

Large cationic molecules antagonize the RI–RNase A interaction.³⁴ Hence, we next sought to determine whether the dendrimer is an antagonist of this interaction. Serial dilutions of a solution of dendrimer were used to compete with a 2',7'-diethylfluorescein-labeled variant of RNase A for binding to RI. Using this assay,³⁵ we determined that the RI-dendrimer complex in PBS has $K_d = (3.1 \pm 0.5) \mu\text{M}$, which is significantly greater than RI-evasive variants of RNase A.¹⁰ This value, along with the known concentration of RI in the cytosol (4 μM ³⁶), indicate that the dendrimer is unlikely to act by antagonizing the RI–RNase A interaction.

Having established that the dendrimer is inert *in vitro*, we sought to test our hypothesis *in cellulo*. Specifically, we determined the effect of the dendrimer on the cytotoxicity of wild-type RNase A and two RI-evasive variants. We did these experiments with K-562 cells, which are nonadherent cells from a human myelogenous leukemia line. We choose dendrimer concentrations of 1 and 10 μM because these concentrations did not compromise important attributes of the ribonucleases (Table 1) and allowed for the unrestricted proliferation of K-562 cells ($97 \pm 3\%$ and $96 \pm 3\%$, respectively).

We found that wild-type RNase A showed no measurable cytotoxicity with or without dendrimer (Figure 3), as expected from its high affinity for RI. In contrast, both 1 and 10 μM dendrimer potentiated the cytotoxicity of two RI-evasive ribonuclease variants, with 10 μM being slightly more effective. At 10 μM dendrimer, G88R RNase A, which is moderately evasive to RI, exhibited a decrease in IC_{50} value of 5-fold. D38R/R39D/N67R/G88R (DRNG) RNase A, which is highly evasive to RI and hence more cytotoxic than the G88R variant, likewise had its cytotoxicity potentiated by 5-fold. Because the dendrimer evoked the same relative increase in cytotoxicity for both variants, we concluded that the dendrimer acts by enhancing either cellular internalization or translocation.

Ribonucleases enter the cytosol by first being internalized into endosomes and then translocating into the cytosol.⁷ To discern whether the dendrimer affected internalization, we attached a fluorogenic label to RNase A, as described previously.³⁷ This label is not fluorescent until entering endosomes, which contain esterases that unmask its fluorescence. K-562 cells were incubated with or without dendrimer (1 or 10 μM), and ribonuclease internalization was measured by flow cytometry. Dendrimer did not increase internalization of the labeled ribonuclease into the cell (Table 1). Apparently, the dendrimer acts downstream of internalization, probably by increasing endosomal escape.

We conclude that a cationic dendrimer can potentiate the cytotoxicity of RI-evasive variants of RNase A *in trans*. This ability obviates the deleterious consequences that typically accompany chemical or mutagenic modification. Although it is unlikely that the particular strategy described here could be used in a clinical setting, our findings do encourage further exploration, both on the use of cationic dendrimers as co-treatments with chemotherapeutic agents and on the mechanism of their action in this context.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We are grateful to Drs. T. J. Rutkoski, L. D. Lavis, T.-Y. Chao, D. R. McCaslin, and R. W. Watkins, as well as J. Lomax for contributive discussions. Experiments made use of the Biophysics Instrumentation Facility, which was established by grants BIR-9512577 (NSF) and S10 RR13790 (NIH). This work was supported by grant R01 CA073808 (NIH).

References and notes

- Matoušek J. *Comp Biochem Physiol*. 2001; 129C:175.
- Leland PA, Raines RT. *Chem Biol*. 2001; 8:405. [PubMed: 11358688]
- Makarov AA, Ilinskaya ON. *FEBS Lett*. 2003; 540:15. [PubMed: 12681476]
- Benito A, Ribó M, Vilanova M. *Mol Biosyst*. 2005; 1:294. [PubMed: 16880994]
- Arnold U, Ulbrich-Hofmann R. *Biotechnol Lett*. 2006; 28:1615. [PubMed: 16902846]
- Dickson KA, Haigis MC, Raines RT. *Prog Nucleic Acid Res Mol Biol*. 2005; 80:349. [PubMed: 16164979]

7. Rutkoski TJ, Raines RT. *Curr Pharm Biotechnol*. 2008; 9:185. [PubMed: 18673284]
8. Lee JE, Raines RT. *BioDrugs*. 2008; 22:53. [PubMed: 18215091]
9. Vasandani VM, Wu YN, Mikulski SM, Youle RJ, Sung C. *Cancer Res*. 1996; 56:4180. [PubMed: 8797589]
10. Rutkoski TJ, Kurten EL, Mitchell JC, Raines RT. *J Mol Biol*. 2005; 354:41. [PubMed: 16188273]
11. Johnson RJ, McCoy JG, Bingman CA, Phillips GN Jr, Raines RT. *J Mol Biol*. 2007; 368:434. [PubMed: 17350650]
12. Raines RT. *Chem Rev*. 1998; 98:1045. [PubMed: 11848924]
13. Leland PA, Schultz LW, Kim BM, Raines RT. *Proc Natl Acad Sci USA*. 1998; 95:10407. [PubMed: 9724716]
14. Leland PA, Staniszewski KE, Kim BM, Raines RT. *J Biol Chem*. 2001; 276:43095. [PubMed: 11555655]
15. Saxena SK, Rybak SM, Winkler G, Meade HM, McGray P, Youle RJ, Ackerman EJ. *J Biol Chem*. 1991; 266:21208. [PubMed: 1939163]
16. Smith MR, Newton DL, Mikulski SM, Rybak SM. *Exp Cell Res*. 1999; 247:220. [PubMed: 10047464]
17. Johnson RJ, Chao TY, Lavis LD, Raines RT. *Biochemistry*. 2007; 46:10308. [PubMed: 17705507]
18. Fuchs SM, Raines RT. *Protein Sci*. 2005; 14:1538. [PubMed: 15930002]
19. Fuchs SM, Rutkoski TJ, Kung VM, Groeschl RT, Raines RT. *Protein Eng Des Sel*. 2007; 20:505. [PubMed: 17954521]
20. Wlodawer A, Svensson LA, Sjölin L, Gilliland GL. *Biochemistry*. 1988; 27:2705. [PubMed: 3401445]
21. Futami J, Maeda T, Kitazoe M, Nukui E, Tada H, Seno M, Kosaka M, Yamada H. *Biochemistry*. 2001; 40:7518. [PubMed: 11412105]
22. Futami J, Kitazoe M, Maeda T, Nukui E, Sakaguchi M, Kosaka J, Miyazaki M, Kosaka M, Tada H, Seno M, Sasaki J, Huh NH, Namba M, Yamada H. *J Biosci Bioeng*. 2005; 99:95. [PubMed: 16233763]
23. Loudet A, Han J, Barhoumi R, Pellois JP, Burghardt RC, Burgess K. *Org Biomol Chem*. 2008; 6:4516. [PubMed: 19039359]
24. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, Roeck J, Ryder J, Smith P. *Polym J*. 1985; 17:117.
25. Esfand R, Tomalia DA. *Drug Discov Today*. 2001; 6:427. [PubMed: 11301287]
26. Cloninger MJ. *Curr Opin Chem Biol*. 2002; 6:742. [PubMed: 12470726]
27. Guillot-Nieckowski M, Eisler S, Diederich F. *New J Chem*. 2007; 31:1111.
28. Navarro G, Maiwald G, Haase R, Rogach AL, Wagner E, de Ilarduya CT, Ogris M. *J Control Release*. 2010; 146:99. [PubMed: 20438778]
29. Roberts JC, Bhalgat MK, Zera RT. *J Biomed Mat Res*. 1996; 30:53.
30. Malik N, Wiwattanapatapee R, Klopsch R, Lorenz K, Frey H, Weener JW, Meijer EW, Paulus W, Duncan R. *J Control Release*. 2000; 65:133. [PubMed: 10699277]
31. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T. *Biomaterials*. 2003; 24:1121. [PubMed: 12527253]
32. Cakara D, Kleimann J, Borkovec M. *Macromolecules*. 2003; 36:4201.
33. Sonawane ND, Szoka FC Jr, Verkman AS. *J Biol Chem*. 2003; 278:44826. [PubMed: 12944394]
34. Moenner M, Chauviere M, Chevaillier P, Badet J. *FEBS Lett*. 1999; 443:303. [PubMed: 10025952]
35. Lavis LD, Rutkoski TJ, Raines RT. *Anal Chem*. 2007; 79:6775. [PubMed: 17672523]
36. Haigis MC, Kurten EL, Raines RT. *Nucleic Acids Res*. 2003; 31:1024. [PubMed: 12560499]
37. Lavis LD, Chao TY, Raines RT. *ACS Chem Biol*. 2006; 1:252. [PubMed: 17163679]

Figure 1.

Electrostatic potential map of the RNase A surface with positively charged surface in blue, negatively charged surface in red, and neutral surface in white. Images were created with PDB entry 7rsa20 and the program PyMOL (DeLano Scientific, San Francisco, CA, USA).

Figure 2. Structure of the generation 2 poly(amidoamine) (PAMAM) dendrimer. The thirty amino nitrogens are in blue.

Figure 3.

Effect of generation 2 PAMAM dendrimer on the inhibition of cancer cell proliferation by ribonucleases. The proliferation of K-562 cells was measured by the incorporation of [*methyl*-³H]thymidine. Data points represent the mean ($\pm$ SE) of three separate experiments performed in triplicate.

Table 1

Effect of dendrimers on RNase A thermostability, and catalytic activity, and cellular internalization

Additive	T_m (°C) ^a	k_{cat}/K_M ($10^6 M^{-1}s^{-1}$) ^b	Internalization (counts) ^c
None	62.7 ± 0.1	33 ± 5	129 ± 9
1 μM Dendrimer	62.8 ± 0.1	34 ± 4	125 ± 1
10 μM Dendrimer	63.2 ± 0.2	28 ± 2	113 ± 7

^aValues of T_m (± SE) were determined in PBS by UV spectroscopy.

^bValues of k_{cat}/K_M (± SE) were determined for catalysis of 6-FAM–dArUdAdA–6-TAMRA cleavage.

^cValues of internalization represent the mean (± SE) from three separate experiments performed in triplicate in which K-562 cells were incubated with an esterase-activatable fluorogenic label for 3 h, and internalization was determined with flow cytometry. The effect of dendrimer on thermostability, catalytic activity, or internalization was not significant ($p > 0.05$).